Mallinckrodt to Present at the BMO Prescriptions for Success Healthcare Conference

On June 17, 2020 Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, reported that it will present on Tuesday, June 23, 2020 at the BMO Prescriptions for Success Healthcare Conference (Press release, Mallinckrodt, JUN 17, 2020, View Source [SID1234561201]). Mark Trudeau, President and Chief Executive Officer, and Bryan Reasons, Executive Vice President and Chief Financial Officer, will represent the company in a fireside chat at 8:00 a.m. Eastern Time. To access the webcast, please refer to the webcast link posted on our site at: http://www.mallinckrodt.com/investors. A replay of the fireside chat will also be available following the meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


STORM Therapeutics announces publication in Nature Reviews Cancer on the role of RNA Modifications in Cancer by Founder Professor Tony Kouzarides

On June 17, 2020 STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies modulating RNA epigenetics, reported that it has published a scientific paper in the peer reviewed journal Nature Reviews Cancer (Press release, STORM Therapeutics, APR 17, 2020, View Source [SID1234561037]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The paper entitled ‘Role of RNA modifications in cancer’ is an authoritative and comprehensive review of the emerging and highly promising field of RNA epigenetics, highlighting pathways implicated in cancer to-date, describing their biological functions and their connections to the disease. The paper, written by Tony Kouzarides and Isaia Barbieri from The Gurdon Institute, The University of Cambridge describes insights into seven different internal RNA modifications, their mechanisms of actions (where known) and the evidence linking them to cancers. See link to paper: View Source

Professor Tony Kouzarides, Founder of STORM Therapeutics and Deputy Director of Gurdon Institute, University of Cambridge, said: "This paper describes the importance of understanding key RNA epitranscriptomic pathways and their implications for a wide range of cancers. It highlights that an increasing number of RNA modifications and the enzymes responsible for their deposition, removal and detection (or writers, erasers and readers) play context-specific roles in a rapidly expanding catalogue of cancers. They are expected to be tractable for development of targeted small molecule therapies for a wide range of those cancers and could additionally enhance the efficacies of current cancer treatments by affecting primary and acquired drug resistance."

Keith Blundy, CEO of STORM Therapeutics, said: "I am delighted to see the publication by our Company Founder of this paper in a world leading journal. The diversity of RNA modifications and the molecular pathways in which they are involved demonstrates this is only the beginning of the era of RNA epigenetics in cancer therapy and treatment of a wide range of other diseases. STORM Therapeutics is the leading company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases. We expect our lead drug candidate, METTL3, to be the first RNA epigenetic drug to enter human clinical trials in 2021."

TG Therapeutics Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma

On June 7, 2020 TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, reported the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting accelerated approval of umbralisib, the Company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma (MZL) and follicular lymphoma (FL) (Press release, TG Therapeutics, JUN 17, 2020, View Source [SID1234561170]). The FDA previously granted umbralisib breakthrough therapy designation (BTD) for MZL and orphan drug designation (ODD) for MZL and FL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, "The completion of this NDA submission marks an important milestone in bringing us one step closer to providing umbralisib as a potential treatment option for patients with relapsed/refractory MZL and FL. As a company this is a very exciting moment for us, as it marks our very first NDA submission, and I commend our team for all their efforts to get to this point." Mr. Weiss continued, "Importantly, I also want to thank the patients, their families and the research teams who participated in these trials. This has been an incredibly impactful year for TG thus far, with several important milestones yet to come, including topline data from the ULTIMATE trials of ublitximab in multiple sclerosis, presentation of full data from the UNITY-NHL FL/MZL cohorts and from the UNITY-CLL Phase 3 trial of umbralisib plus ublituximab (U2), and a BLA/NDA submission for U2 in chronic lymphocytic leukemia targeted by the end of the year."

ABOUT THE UNITY-NHL PHASE 2b STUDY—MZL & FL COHORTS
The UNITY- NHL trial is a multicenter, open-label Phase 2b trial.

The MZL cohort was designed to evaluate the safety and efficacy of single agent umbralisib, in patients with MZL who have received at least one prior anti-CD20 regimen. In February of 2019, the Company announced that the primary endpoint of overall response rate (ORR) as determined by Independent Review Committee (IRC) was met for all treated MZL patients (n=69). The results met the Company’s target guidance of 40-50% ORR. Interim safety and efficacy data from the MZL cohort were presented in oral presentations in 2019 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting, the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting and the International Conference on Malignant Lymphoma (ICML).

The FL cohort was designed to evaluate the safety and efficacy of single agent umbralisib in patients with FL who have received at least two prior lines of therapy, including an anti-CD20 regimen and an alkylating agent. In October of 2019, the Company announced that the primary endpoint of ORR as determined by IRC was met for all treated FL patients (n=118). The results met the Company’s prespecified response target of 40-50% ORR.

ABOUT MARGINAL ZONE LYMPHOMA
Marginal zone lymphoma (MZL) comprises a group of indolent (slow growing) B-cell non-Hodgkin lymphomas (NHLs) that begin forming in the marginal zone of lymphoid tissue. With an annual incidence of approximately 7,500 newly diagnosed patients in the United States1, MZL is the third most common B-cell NHL, accounting for approximately eight percent of all NHL cases. MZL consists of three different subtypes: extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL)2.

ABOUT FOLLICULAR LYMPHOMA
Follicular lymphoma (FL) is typically a slow-growing or indolent form of non-Hodgkin lymphoma (NHL) that arises from B-lymphocytes, making it a B-cell lymphoma. Follicular lymphoma is generally not curable and is a chronic disease. Patients can live for many years with this form of lymphoma. With an annual incidence in the United States of approximately 15,000 newly diagnosed patients3, FL is the most common indolent lymphoma accounting for approximately 20 percent of all NHL cases4.

Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

On June 17, 2020 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported that it has commenced an underwritten public offering of its common stock and, in lieu of common stock, Leap intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock (Press release, Leap Therapeutics, JUN 17, 2020, View Source [SID1234561186]). All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Leap. Leap intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the securities offered in the public offering. The offering is subject to market, regulatory, and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler & Co. and Raymond James & Associates, Inc. will act as book-running managers for the offering.

Leap intends to use the net proceeds from the offering to fund: (i) the continued development of DKN-01; (ii) manufacturing of clinical trial material; and (iii) general corporate purposes, including working capital and other general and administrative expenses.

The securities will be issued pursuant to an effective shelf registration statement on Form S-3 (File No. 333-223419) that was previously filed by Leap with the Securities and Exchange Commission (the "SEC") on March 2, 2018 and was declared effective by the SEC on March 16, 2018. A preliminary prospectus supplement and the related prospectus will be filed with the SEC and will be available for free on the SEC’s website at View Source Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from: Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN, 55402, by telephone at (800) 747-3924, or by email at [email protected]. These documents may also be obtained from: Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, or by telephone at (800) 248-8863, or e-mail at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference

On June 17, 2020 MannKind Corporation (NASDAQ:MNKD) reported that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET (9 am PT) (Press release, Mannkind, JUN 17, 2020, View Source [SID1234561203]). Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Pharm D.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be posted under the investors section of MannKind’s website under events & presentations or can be accessed at www.lythampartners.com/virtual. A replay of the presentation will be available following the event.

Management will also be participating in virtual one-on-one meetings with institutional investors on June 24, 2020. To arrange a meeting, please contact Robert Blum of Lytham Partners at [email protected] or visit www.lythampartners.com/virtual.